Sirona Biochem Corp. · OTC:SRBCF
Sirona Biochem — Investor Presentation (May 2024)
26 slides from Sirona Biochem's investor presentation, May 8, 2024
Slide 1: Investor Presentation
EN INVESTOR PRESENTATION May 8, 2024 TSX-V: SBM FSE: ZSB | OTC: SRBCF ADVANCING CHEMISTRY. ENHANCING HEALTH
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks a
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specializes in stabilizing carbohydrate molecules to improve efficacy and safety. Sirona Biochem’s business
Slide 4: Share Information
SHARE INFORMATION TSX VENTURE EXCHANGE SBM OTC EXCHANGE SRBCF FRANKFURT STOCK EXCHANGE ZSB FUNDAMENTAL DATA (CAD) TSX-V SBM CAD$0.065 USD$0.052 EUR€0.04 Shares Outstanding 256,454,505 Shares Fully Diluted 254,054,505 Share Price (CAD) $0.065 Shares owned by Insiders: 15% Market Cap $16,513,543 Year
Slide 5: Business Model & Strategy
BUSINESS MODEL & STRATEGY Sirona Biochem’s strategy involves bringing innovative patented compounds to market while also engaging in partnerships to license or sell them to prominent global enterprises. In exchange, receiving income generating sales, front-end fees, milestone payments, and ongoing r
Slide 6: Product Pipeline
PRODUCT PIPELINE Sirona Biochem has invested extensively in developing its products to meet the need of patients and industry partners. The compounds created through our proprietary platform go through rigorous tests and regulatory scrutiny to verify their safety and efficacy. TSX-V: SBM | FSE: ZSB
Slide 7: Cosmetic Products
COSMETIC PRODUCTS Therapeutic Area Compound Status Skincare - Dark spot corrector TFC-1067 & family of • Exclusive licensing deal with AbbVie for TFC-1067 signed for cosmetic use. Available to (Rx & OTC) dark spot correctors license for therapeutic use. Cell Preservation & Repair Glycoprotein Librar
Slide 8: Worldwide IP Portfolio
WORLDWIDE IP PORTFOLIO Sirona Biochem has a strong IP portfolio, including a recently filed patent for its breakthrough anti-aging compound GlycoProteMim™ (TFC-1326), managed by intellectual property law firm Cabinet Regimbeau TSX-V: SBM | FSE: ZSB | OTC: SRBCF 8 www.sironabiochem.com
Slide 9: Milestones
MILESTONES Milestones achieved in the last 18 months: Completed an exclusive, global license with AbbVie for TFC-1067 Completed the terms of manufacturing and supply of TFC-1067 for AbbVie Published research in the renowned Journal of Cosmetic Dermatology Reached first product commercializat
Slide 10: Redefining Anti-Aging Science
Redefining Anti-Aging Science GlycoProteMim™ (TFC-1326) represents a paradigm shift in the world of anti-aging skincare. Our cutting-edge active ingredient is the culmination of over US$15 million in research and development spanning 23 years. Inspired by nature’s own protective mechanisms, GlycoPro
Slide 11: TFC-1326 (GlycoProteMim™): The Science
TFC-1326 (GlycoProteMim™): The Science Novel Non-invasive Anti-Aging Anti-Wrinkle Technology GlycoProteMim™ is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. Dr. Géraldine Deliencourt-Godefroy developed and perfected Gly
Slide 12: TFC-1326 (GlycoProteMim™): Studies and Results
TFC-1326 (GlycoProteMim™): Studies and Results Clinical Trial for GlycoProteMim™ in Paris The clinical trial was designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation was a cream base with Gly
Slide 13: Results of using GlycoProteMim™ after 12 Weeks
Results of using GlycoProteMim™ after 12 Weeks Before After Skin is visibly more radiant and clear Visible wrinkle reduction Improved skin quality and density Face reshaped due to tighter skin Reduced inflammation *Unretouched photos, taken in standard lighting. Results may vary To best understand i
Slide 14: TFC-1326 (GlycoProteMim™): Advantage
TFC-1326 (GlycoProteMim™): Advantage GlycoProteMim™ stands out as a beacon of innovation and safety. Unlike traditional alternatives such as toxins, dermal fillers, and retinoids, GlycoProteMim™ offers a unique solution that is safe and effective in reversing skin aging. Safety for All Skin Types Na
Slide 15: GlycoProteMim™ vs other anti-aging Compounds: Table
GlycoProteMim™ vs other anti-aging Compounds: Table GlycoProteMim (TFC - 1326) Toxins Dermal Fillers Retinoids Unique patented Compound owned by Botox®, Dysport®, Xeomin®, Juvéderm®, Multiple others Tretinoin, Retinaldehyde, Retinol, Retinal, Retinyl Sirona Biochem Jeuveau™ acetate, Retinyl propiona
Slide 16: Introducing Sirona Laboratories™
Introducing Sirona Laboratories™, our new wholly-owned cosmetics subsidiary. Established with a vision to maximize the commercial potential of our breakthrough anti-aging skincare ingredient, GlycoProteMim™. Sirona Laboratories represents a strategic leap into the aesthetics market and the future of
Slide 17: Changing the Game
Changing the Game Through Sirona Laboratories™, we are aiming to achieve several ambitious goals. Our primary objectives include establishing GlycoProteMim™ as the new “Gold Standard” in anti-aging skincare ingredients, while also setting new standards in effectiveness and safety. To realize these g
Slide 18: Global Launch Plan
Global Launch Plan P1 P2 P1 P3 P3 P2 P3 PHASES OF DISTRIBUTION Phase 1 - Q1 2025 - USA - Canada Phase 2 - Q4 2025 - Europe - Gulf States P2 - Australia & New Zealand Phase 3 - China - South Korea - Japan TSX-V: SBM | FSE: ZSB | OTC: SRBCF 18 www.sironabiochem.com
Slide 19: Anticipated Product Line
Anticipated Product Line Anti-Aging Series Therapeutic Series - Anti-Aging Serum Ampoules - Anti-Cellulite Cream - (0.5%) Anti-Aging Cream - Hand Cream - (0.2%) Mild Anti-Aging Cream TSX-V: SBM | FSE: ZSB | OTC: SRBCF 19 www.sironabiochem.com
Slide 20: Facilities/Manufacturing Partner
FACILITIES/MANUFACTURING PARTNER Sirona Biochem Laboratory Manufacturing Partner - TFC-1067 Anti-aging: GlycoProteMim™ TFChem Laboratory, France WuXi AppTec, China Laboratory WuXi AppTec provides a broad R&D and DIVA Laboratory, France The 502-square-meter laboratory is located in Val de Reuil, Fran
Slide 21: Technology
TECHNOLOGY Our world-class team is comprised of award-winning scientists who have worked for Fortune 500 companies such as Sanofi, GSK and Bayer. TSX-V: SBM | FSE: ZSB | OTC: SRBCF 21 www.sironabiochem.com
Slide 22: Carbohydrate compounds have immense commercial potential
Carbohydrate compounds have immense commercial potential. • They are involved in many of our body’s biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics Examples of successful carbohydrate-based drugs are: • Anti-viral medications such as Tami
Slide 23: Management
MANAGEMENT Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a
Slide 24: Christopher Hopton, CPA, CGA
Christopher Hopton, Sirona Biochem’s Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hop
Slide 25: Contact Us
CONTACT US Sirona Biochem: Corporate Office TFChem: Laboratory Parent Company - founded 2009 Wholly Owned Subsidiary - acquired in 2011 Sirona Biochem Corp. TFChem c/o WeWork Voie de l’innovation 595 Burrard Street, Pharma Parc II Vancouver, BC 27100 Val de Reuil V7X 1L4 France PHONE: +1.604.641.446
Slide 26: TSX-V: SBM
TSX-V: SBM FSE: ZSB | OTC: SRBCF